Welcome to our dedicated page for Celcuity SEC filings (Ticker: CELC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Celcuity Inc means dissecting dense disclosures on trial endpoints, R&D burn, and licensing terms—details that can span hundreds of pages. If you have ever wondered where to locate the latest Celcuity quarterly earnings report 10-Q filing or how to decode a 300-page 10-K, you are not alone.
Stock Titan’s AI engine digests every sentence the moment it hits EDGAR, then delivers concise explanations in plain English. The result: Celcuity SEC filings explained simply. Whether you need understanding Celcuity SEC documents with AI or instant alerts on Celcuity Form 4 insider transactions real-time, our platform turns regulatory text into actionable context.
- 10-K: Get the Celcuity annual report 10-K simplified—clinical pipeline progress, cash runway, and risk factors, all summarized.
- 10-Q: Compare quarter-over-quarter R&D spend with automated charts and Celcuity earnings report filing analysis.
- 8-K: Stay ahead with Celcuity 8-K material events explained—from Phase 3 data releases to financing rounds.
- Form 4: Monitor Celcuity insider trading Form 4 transactions and track each Celcuity executive stock transactions Form 4 in real time.
- DEF 14A: Review the Celcuity proxy statement executive compensation section with AI-highlighted pay metrics.
Every filing is updated the moment Celcuity submits it, complete with AI-powered summaries, key-metric extractions, and side-by-side document comparisons. Skip the biotech jargon, save hours of manual reading, and focus on the insights that move Celcuity’s valuation.
Celcuity Inc. reported interim financial details showing material financing and capital activity supporting its clinical programs. The company amended and restated a loan agreement that provided initial borrowings including Term A, B and C loans and contemplates additional tranches (Term D, Term E and optional Term F) tied to milestones and covenants; the Term Loans mature May 1, 2029 and bear variable interest with a portion payable in-kind. Innovatus has limited conversion and warrant rights tied to the loan.
Subsequent events include a completed equity offering of 1,836,842 shares and pre-funded warrants and the issuance of $201.25 million aggregate principal amount of 2.75% Convertible Senior Notes due 2031, generating approximately $194.9 million net proceeds. The company recognized a $5.0 million upfront license fee and issued $5.0 million in common stock to Pfizer and recorded a related R&D expense tied to an NDA filing deemed probable. Outstanding common shares increased to 38,914,208 as of June 30, 2025; no dividends were declared.
Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. have filed Amendment No. 3 to Schedule 13G on Celcuity Inc. (NASDAQ: CELC). As of 30 June 2025 the group beneficially owns 1,633,208 common shares, equal to 4.31 % of the 37,866,358 shares outstanding (per Celcuity’s 15 May 2025 SEC filing). Because the position now stands at or below the 5 % threshold, Item 5 is checked, signalling ownership of �5 percent or less of a class.�
The shares are held directly by the Cayman-based Perceptive Life Sciences Master Fund. Voting and dispositive power over the full block is shared among the Master Fund, Perceptive Advisors (investment manager) and Mr. Edelman (managing member). None of the reporting persons holds sole voting or dispositive power. The filing states the securities were not acquired to influence control of the issuer. Signatures are dated 4 Aug 2025.
FAQ
What is the current stock price of Celcuity (CELC)?
What is the market cap of Celcuity (CELC)?
